-
18-02-2014, 01:49 PM
#331
Rules are rules - and best to conform to them if you might get caught
Originally Posted by 1leon
But is an an upgrade really warranted? Previous indication $90-$95m new $97--surely coming in, if it does, at $97m is pretty close to range up to $95m. Are we really now going to see upgrades for companies for the sake of $2m?
If they gave guidance of $90-95M then they have to update the market if they know that the result is likely to be outside that range.
Best Wishes
Paper Tiger
-
18-02-2014, 02:20 PM
#332
Member
Originally Posted by Paper Tiger
If they gave guidance of $90-95M then they have to update the market if they know that the result is likely to be outside that range.
Best Wishes
Paper Tiger
Thanks but is "approximately $97m" subject to continuation of exchange rates clearly outside $95m. What range does approximately $97m cover? These are pretty fine calculations if you have to be within 1-2%.
-
18-02-2014, 02:21 PM
#333
Member
Originally Posted by Paper Tiger
If they gave guidance of $90-95M then they have to update the market if they know that the result is likely to be outside that range.
Best Wishes
Paper Tiger
Thanks but is "approximately $97m" subject to continuation of exchange rates clearly outside $95m. What range does approximately $97m cover? These are pretty fine calculations if you have to be within 1-2%.
-
18-02-2014, 02:31 PM
#334
Not sure that I see the problem
Ok before you had $92.5M +/-2.5M and now you have $97M +/- (say) $2M
You sure would want to know if went to approximately $88M, would you not?
So go with it, share and enjoy.
Best Wishes
Paper Tiger
-
18-02-2014, 02:38 PM
#335
Originally Posted by snapiti
I must say an announcement to upgarde the profit which is only 2.5% out of the range is a bit of a surprise.
Under continuous disclosure, if any statement made is incorrect, it must be corrected. As PT said, if it was a drop, you would want the disclosure.
-
18-02-2014, 04:19 PM
#336
Member
Originally Posted by Paper Tiger
Ok before you had $92.5M +/-2.5M and now you have $97M +/- (say) $2M
You sure would want to know if went to approximately $88M, would you not?
So go with it, share and enjoy.
Best Wishes
Paper Tiger
Frankly no. I have never made any decision based on a 2% movement in profit up or down. If approximately $88m encompasses $90m we are no further ahead. Add to that currency movement has been a big factor in FPH results, or lack of result, over many years.
-
18-02-2014, 05:09 PM
#337
Your so vain - I bet you think this post is about you
Originally Posted by 1leon
Frankly no. I have never made any decision based on a 2% movement in profit up or down. If approximately $88m encompasses $90m we are no further ahead. Add to that currency movement has been a big factor in FPH results, or lack of result, over many years.
To put my final word in on the need for this profit upgrade announcement.
There are NZX rules with guidance notes that FPH has to follow (the rules bit) and this is one of those circumstances (see Section 10 of the rules and the Continuous Disclosure Guidance Note).
I have checked, and there is no waiver even in circumstances where one of their shareholders has a poor grasp of arithmetic.
Best Wishes
Paper Tiger
-
15-05-2014, 11:07 PM
#338
Member
Looking forward to results 23 MAY 2014, been a good invest for me so far.
Why today is a good day to buy Fisher & Paykel Healthcare Corp Ltd
http://www.fool.com.au/2014/05/15/wh...care-corp-ltd/
Last edited by Microsloth; 15-05-2014 at 11:09 PM.
-
23-05-2014, 09:30 AM
#339
Member
Good year for FPH
FPH delivers record full year result, net profit up 26%
• 26% growth in net profit after tax to a record NZ$97.1 million, 46% growth in constant currency.
• 12% growth in operating revenue to a record NZ$623.4 million, 13% growth in constant currency.
• Double digit operating revenue growth in both of the company’s major product groups – Respiratory and acute care (RAC) 14%, Obstructive Sleep Apnea (OSA) 15% in constant currency.
• New RAC applications consumables revenue outside of invasive ventilation grew particularly strongly at 29% in constant currency.
• Strong performance from new OSA masks, Eson, Pilairo Q and Simplus, drove mask operating revenue growth of 23% in constant currency.
• Gross margin improvement of 327 basis points for the full year, 393 bps in constant currency.
• Fully imputed final dividend of 7.0 cps.
• Investment in R&D increased by 18% to NZ$54.1 million, representing 8.7% of operating revenue.
-
23-05-2014, 09:37 AM
#340
conference call today scheduled to begin at 10:00am
To listen to the webcast, access the company’s website at www.fphcare.com/investor. Please allow extra time prior to the webcast to visit the site and download the streaming media software if required. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.
To attend the conference call, participants will need to dial in to one of the numbers below at least 5 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 40710638.
New Zealand Toll Free 0800 446 046
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks